Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by PharmAla Biotech
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
MDXXF
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
PMBHF
PharmAla Begins Trading on OTCQB
September 06, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
PMBHF
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
July 31, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
PMBHF
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
June 09, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
PMBHF
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
ASX:VIT
CSE:MDMA
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
February 03, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
November 16, 2022
From
PharmAla Biotech
Via
GlobeNewswire
Tickers
CSE:MDMA
CSE:MSET
MSSTF
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.